Literature DB >> 21252240

Impaired regulation of the incretin effect in patients with type 2 diabetes.

Jonatan I Bagger1, Filip K Knop, Asger Lund, Henrik Vestergaard, Jens J Holst, Tina Vilsbøll.   

Abstract

OBJECTIVE: In healthy subjects, the incretin effect during an oral glucose tolerance test increases with the size of glucose load, resulting in similar glucose excursions independently of the glucose loads. Whether patients with type 2 diabetes mellitus (T2DM) are able to regulate their incretin effect is unknown. RESEARCH DESIGN AND METHODS: Incretin effect was measured over 6 d by means of three 4-h oral glucose tolerance test with increasing glucose loads (25, 75, and 125 g) and three corresponding isoglycemic iv glucose infusions in eight patients with T2DM [fasting plasma glucose, mean 7.7 (range 7.0-8.9) mM; glycosylated hemoglobin, 7.0% (6.2-8.4%)] and eight matched healthy control subjects [fasting plasma glucose, 5.3 (4.8-5.7) mM; glycosylated hemoglobin, 5.4% (5.0-5.7%)].
RESULTS: Patients with T2DM exhibited higher peak plasma glucose in response to increasing oral glucose loads, whereas no differences in peak plasma glucose values among control subjects were observed. The incretin effect was significantly (P < 0.003) lower in patients with T2DM (0 ± 7, 11 ± 9, and 36 ± 5%) as compared with control subjects (36 ± 5, 53 ± 6, and 65 ± 6%). Equal and progressively delayed gastric emptying due to the increasing loads was found in both groups. Incretin hormone responses were similar.
CONCLUSIONS: Up-regulation of the incretin effect in response to increasing oral glucose loads seems to be crucial for controlling glucose excursions in healthy subjects. Patients with T2DM are characterized by an impaired capability to regulate their incretin effect, which may contribute to the exaggerated glucose excursions after oral ingestion of glucose in these patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21252240     DOI: 10.1210/jc.2010-2435

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  52 in total

1.  Glucose sensing by gut endocrine cells and activation of the vagal afferent pathway is impaired in a rodent model of type 2 diabetes mellitus.

Authors:  Jennifer Lee; Bethany P Cummings; Elizabeth Martin; James W Sharp; James L Graham; Kimber L Stanhope; Peter J Havel; Helen E Raybould
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-07       Impact factor: 3.619

Review 2.  Impact of postprandial glycaemia on health and prevention of disease.

Authors:  E E Blaak; J-M Antoine; D Benton; I Björck; L Bozzetto; F Brouns; M Diamant; L Dye; T Hulshof; J J Holst; D J Lamport; M Laville; C L Lawton; A Meheust; A Nilson; S Normand; A A Rivellese; S Theis; S S Torekov; S Vinoy
Journal:  Obes Rev       Date:  2012-07-11       Impact factor: 9.213

3.  Modulation of Glucagon-like Peptide-1 (GLP-1) Potency by Endocannabinoid-like Lipids Represents a Novel Mode of Regulating GLP-1 Receptor Signaling.

Authors:  Yu-Hong Cheng; Mei-Shang Ho; Wei-Ting Huang; Ying-Ting Chou; Klim King
Journal:  J Biol Chem       Date:  2015-04-22       Impact factor: 5.157

4.  The amount and types of fatty acids acutely affect insulin, glycemic and gastrointestinal peptide responses but not satiety in metabolic syndrome subjects.

Authors:  Chee-Yan Chang; M S Kanthimathi; Alexander Tong-Boon Tan; Kalanithi Nesaretnam; Kim-Tiu Teng
Journal:  Eur J Nutr       Date:  2016-09-08       Impact factor: 5.614

Review 5.  Physiology of incretins in health and disease.

Authors:  Carolyn F Deacon; Bo Ahrén
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 6.  Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.

Authors:  Robert E Steinert; Christine Feinle-Bisset; Lori Asarian; Michael Horowitz; Christoph Beglinger; Nori Geary
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

7.  Esophageal and Gastric Dysmotilities are Associated with Altered Glucose Homeostasis and Plasma Levels of Incretins and Leptin.

Authors:  Rebecka Hammersjö; Bodil Roth; Peter Höglund; Bodil Ohlsson
Journal:  Rev Diabet Stud       Date:  2016-05-10

8.  The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?

Authors:  Benedikt A Aulinger; Torsten P Vahl; Ron L Prigeon; David A D'Alessio; Deborah A Elder
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-03-15       Impact factor: 4.310

9.  Application of the integrated glucose-insulin model for cross-study characterization of T2DM patients on metformin background treatment.

Authors:  Joanna Parkinson; Bengt Hamrén; Maria C Kjellsson; Stanko Skrtic
Journal:  Br J Clin Pharmacol       Date:  2016-08-16       Impact factor: 4.335

Review 10.  Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies.

Authors:  S Calanna; M Christensen; J J Holst; B Laferrère; L L Gluud; T Vilsbøll; F K Knop
Journal:  Diabetologia       Date:  2013-02-03       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.